Work

A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer

Year: 2011

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-011-9708-3

Authors: Jason E. Faris, Jamie Arnott, Hui Zheng, David P. Ryan, Thomas A. Abrams, Lawrence S. Blaszkowsky, Jeffrey W. Clark, Peter C. Enzinger, Aram F. Hezel, Kimmie Ng, Brian M. Wolpin, Eunice L. Kwak

Institutions: Massachusetts General Hospital, CASI Pharmaceuticals (United States), Dana-Farber Cancer Institute, University of Rochester Medicine, University of Rochester

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute

Awards: G1423636853, G1460768082, Cohort Study of Biochemical and Genetic Risk Factors for Pancreatic Cancer

OpenAlex ID: W2034303073

FWCI: 0.551

Cites: 16

Cited by: 8

Related to: 10